Becton, Dickinson and Company (NYSE:BDX)’s share price hit a new 52-week high during mid-day trading on Thursday following a better than expected earnings announcement. The company traded as high as $221.61 and last traded at $0.00, with a volume of shares changing hands. The medical instruments supplier reported $2.40 EPS for the quarter, topping analysts’ consensus estimates of $2.37 by $0.03. The firm had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.14 billion. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The business’s revenue for the quarter was down 2.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.12 earnings per share.

A number of research analysts have recently commented on the stock. Barclays PLC reissued an “equal weight” rating and issued a $210.00 target price (up previously from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $230.00 target price (up previously from $210.00) on shares of Becton, Dickinson and in a report on Friday. Morgan Stanley increased their target price on shares of Becton, Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a report on Friday. Stifel Nicolaus reissued a “buy” rating and issued a $245.00 target price on shares of Becton, Dickinson and in a report on Friday. Finally, BidaskClub cut shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Five equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $211.94.

In other Becton, Dickinson and news, insider Gary M. Cohen sold 15,044 shares of the stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $200.43, for a total transaction of $3,015,268.92. Following the completion of the sale, the insider now owns 95,270 shares of the company’s stock, valued at approximately $19,094,966.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ellen R. Strahlman sold 9,283 shares of the stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the sale, the insider now directly owns 26,638 shares of the company’s stock, valued at approximately $5,279,917.98. The disclosure for this sale can be found here. Insiders sold 75,904 shares of company stock valued at $15,242,688 in the last ninety days. 1.40% of the stock is currently owned by insiders.

Large investors have recently added to or reduced their stakes in the business. Almanack Investment Partners LLC. acquired a new stake in Becton, Dickinson and during the 1st quarter valued at approximately $105,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in Becton, Dickinson and by 55.8% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after purchasing an additional 240 shares during the period. Parkside Financial Bank & Trust increased its position in Becton, Dickinson and by 8.1% during the 2nd quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock valued at $133,000 after purchasing an additional 51 shares during the period. Harfst & Associates Inc. increased its position in Becton, Dickinson and by 46.4% during the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after purchasing an additional 221 shares during the period. Finally, Financial Architects Inc increased its position in Becton, Dickinson and by 8.0% during the 2nd quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock valued at $142,000 after purchasing an additional 54 shares during the period. 86.70% of the stock is owned by institutional investors and hedge funds.

The company has a debt-to-equity ratio of 1.48, a quick ratio of 5.01 and a current ratio of 5.56. The company has a market capitalization of $50.98 billion, a PE ratio of 23.61, a price-to-earnings-growth ratio of 1.77 and a beta of 1.04.

TRADEMARK VIOLATION NOTICE: “Becton, Dickinson and Company (BDX) Sets New 12-Month High on Strong Earnings” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.watchlistnews.com/becton-dickinson-and-company-bdx-sets-new-12-month-high-on-strong-earnings/1676936.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.